Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-A9-0631
- Development stage
- Phase 1
- Lead developer
- Alpha-9 Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
[177Lu]Lu-A9-0631 is a radioligand therapy (RLT) developed by Alpha-9 Oncology for the treatment of advanced solid tumors that express the Gastrin-Releasing Peptide Receptor (GRPR). The drug is composed of a high-affinity peptide ligand specific for GRPR, conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu). GRPR is a G protein-coupled receptor that is frequently overexpressed in various malignancies, including prostate, breast, and colorectal cancers, while maintaining low expression in healthy tissues. Upon intravenous administration, [177Lu]Lu-A9-0631 selectively binds to GRPR-positive tumor cells, where the Lutetium-177 isotope delivers localized ionizing radiation, causing DNA damage and subsequent cell death. It is currently being investigated in Phase 1/1b clinical trials as part of a theranostic platform that includes alpha-emitting and imaging counterparts.
- Other names
- 177Lu-A9-0631
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on [177Lu]Lu-A9-0631.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-A9-0631.